Literature DB >> 27146065

Clinical evaluation of (18)F-fludeoxyglucose positron emission tomography/CT using point spread function reconstruction for nodal staging of colorectal cancer.

Kazuya Kawashima1, Kenichi Kato1, Makiko Tomabechi1, Mikaru Matsuo1, Koki Otsuka2, Kazuyuki Ishida3, Ryuji Nakamura4, Shigeru Ehara1.   

Abstract

OBJECTIVE: For patients with colorectal cancer, lymph node metastasis is a very important factor for prognostic and treatment determinations. Fluorine-18 fludeoxyglucose positron emission tomography/CT ((18)F-FDG-PET/CT) is among the useful tools for detecting lymph node metastasis. Recently, a new (18)F-FDG-PET/CT reconstruction technique for improving spatial resolution and signal-to-noise ratios, point spread function (PSF), has become available. We assessed the effect of PSF reconstruction on standardized uptake values and its diagnostic accuracy for lymph node staging in patients with colorectal cancer.
METHODS: We retrospectively analysed records from patients with colorectal cancer who underwent (18)F-FDG-PET/CT for pre-operative staging. All positron emission tomography CT (PET/CT) examinations were reconstructed using ordered subset expectation maximization (OSEM) and OSEM + PSF. We compared sensitivities, specificities, positive-predictive values (PPVs), negative-predictive values (NPVs) and accuracies of conventional PET/CT (reconstructed with OSEM) and PSF-PET/CT (reconstructed with OSEM + PSF) for identifying lymph node metastases. We also analysed the diagnostic confidence level on a 5-point scale.
RESULTS: With conventional PET/CT, the sensitivity, specificity, PPV, NPV and accuracy were 53.1%, 99.1%, 94.4%, 88.3% and 89.1%, respectively. With PSF PET/CT, the corresponding values were 65.6%, 99.1%, 95.4%, 91.2% and 91.8%, respectively. Conventional PET/CT and PSF PET/CT did not differ significantly in terms of N-stage definition (p = 0.125). However, the diagnostic confidence level of PSF PET/CT was significantly higher than that of conventional PET/CT (p < 0.01).
CONCLUSION: PSF reconstruction might slightly increase sensitivity without impairing specificity. Moreover, this technique is expected to facilitate more confident radiological decisions when compared with conventional PET/CT. Advance in knowledge: This study demonstrates the clinical effectiveness of PSF PET/CT for lymph node staging in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27146065      PMCID: PMC5257305          DOI: 10.1259/bjr.20150938

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  15 in total

1.  Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.

Authors:  Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

2.  Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.

Authors:  Charline Lasnon; Rodney J Hicks; Jean-Mathieu Beauregard; Alvin Milner; Maria Paciencia; Anne-Valérie Guizard; Stéphane Bardet; Radj Gervais; Gabriel Lemoel; Gérard Zalcman; Nicolas Aide
Journal:  Clin Nucl Med       Date:  2012-10       Impact factor: 7.794

3.  Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors:  Dimitri Bellevre; Cécile Blanc Fournier; Odile Switsers; Audrey Emmanuelle Dugué; Christelle Levy; Djelila Allouache; Cédric Desmonts; Hubert Crouet; Jean-Marc Guilloit; Jean-Michel Grellard; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

4.  Prognosis of node-positive colon cancer.

Authors:  A M Cohen; S Tremiterra; F Candela; H T Thaler; E R Sigurdson
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

5.  Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT.

Authors:  Yoshiyuki Tsunoda; Masaaki Ito; Hirofumi Fujii; Hiroyuki Kuwano; Norio Saito
Journal:  Jpn J Clin Oncol       Date:  2008-04-19       Impact factor: 3.019

6.  Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.

Authors:  Iva Kantorová; Ludmila Lipská; Otakar Bêlohlávek; Vladimír Visokai; Miroslav Trubaĉ; Michaela Schneiderová
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

7.  Utility of high-definition FDG-PET image reconstruction for lung cancer staging.

Authors:  Yoshiyuki Ozawa; Masaki Hara; Yuta Shibamoto; Tsuneo Tamaki; Masami Nishio; Kumiko Omi
Journal:  Acta Radiol       Date:  2013-05-12       Impact factor: 1.990

8.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

9.  [Usefulness of Determining Acquisition Time by True Count Rate Measurement Method for Delivery 18F-FDG PET/CT].

Authors:  Shota Miura; Satoshi Odashima
Journal:  Nihon Hoshasen Gijutsu Gakkai Zasshi       Date:  2016-03

10.  What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer.

Authors:  Monique Maas; Iris J G Rutten; Patty J Nelemans; Doenja M J Lambregts; Vincent C Cappendijk; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-06       Impact factor: 9.236

View more
  3 in total

Review 1.  Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis.

Authors:  Matthijs C F Cysouw; Gerbrand M Kramer; Linda J Schoonmade; Ronald Boellaard; Henrica C W de Vet; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-04       Impact factor: 9.236

2.  New PET technologies - embracing progress and pushing the limits.

Authors:  Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-03       Impact factor: 9.236

3.  Diagnostic performance of 18F-FDG PET/CT using point spread function reconstruction on initial staging of rectal cancer: a comparison study with conventional PET/CT and pelvic MRI.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Hideaki Yano; Yoshimasa Gohda; Yasutaka Shuno
Journal:  Cancer Imaging       Date:  2018-01-30       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.